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The 10th International Workshop on 
Langerhans Cells,* held 3–4 September 
2007 in Berne, Switzerland, was 
organized by Lasse Braathen, Robert 
Hunger, and Nikhil Yawalkar (all of 
Berne) and Sem Saeland (Lyon, France). 
This report emphasizes some of the 
cutting-edge research and several key 
issues discussed at this meeting.
Langerhans cells ontogeny
In the past few years, it has become 
evident from the study of mouse mod-
els that the dendritic cells (DCs) of 
the epidermis, Langerhans cells (LCs), 
have a life cycle quite distinct from 
that of many other types of DCs. They 
self-renew locally throughout life and 
require input from bone marrow pre-
cursors only after severe skin injury that 
may deplete local LC precursors (Merad 
et al., 2002). When such bone marrow 
precursors are needed, they appear to 
derive from monocytes (Ginhoux et al., 
2006). New work presented by Julia 
Ober-Blobaum from Martin Zenke’s 
laboratory (Aachen, Germany) further 
explored an observation that the inhibi-
tor of DNA binding (Id2) is induced by 
transforming growth factor-β and that 
mice deficient in Id2 lack LCs (Hacker 
et al., 2003). Dr. Ober-Blobaum 
observed a differential dependency on 
Id2 for local LC establishment at birth 
and ongoing maintenance in the steady 
state and the replenishment of LCs in 
injured skin because the repopulation 
of injured skin with LCs was indepen-
dent of Id2. These data suggest that LC 
replenishment in highly inflamed skin 
uses a completely different pathway 
from the one followed during develop-
ment. These findings fit well with new 
data presented by Miriam Merad (New 
York, NY) that corroborated the concept 
that the embryonic LC precursor was 
distinct from circulating blood leuko-
cyte populations present in adult mice.
Identification of langerin-positive 
dendritic cells, distinct from Langerhans 
cells, in the mouse dermis
To understand LCs, one must be able 
to trace them definitively. Langerin, 
a protein associated with the distinc-
tive Birbeck granules of LCs, has been 
thought to selectively identify LCs in 
skin (Valladeau et al., 2000). When 
langerin-positive cells were detected in 
the dermis in the past, it was suggested 
that they were LCs that had left the epi-
dermis and were on their way to down-
stream lymph nodes (LNs), passing 
through the dermis. At the conference, 
it became clear that this is not the case. 
Instead, a proportion of the dermal lan-
gerin-positive cells comprise a distinct 
population on their own. Three talks, 
given by Sandrine Henri from Bernard 
Malissen’s group (Marseille, France), 
Florent Ginhoux from Miriam Merad’s 
laboratory (New York, NY), and Dan 
Kaplan in collaboration with Kristin 
Hogquist (Minneapolis, MN) discussed 
the characterization of a population of 
langerin-positive DCs independent of 
migratory LCs in mice dermis. Using 
a knockin mouse obtained from Dr. 
Malissen, in which diphtheria toxin 
receptor (DTR) is expressed under the 
langerin promoter (DTR-langerin mice) 
(Kissenpfennig et al., 2005), Henri, 
Ginhoux, and Kaplan showed that after 
DT treatment langerin-positive DCs 
reappear in the dermis and in the LNs 
weeks before LCs reappear in the epi-
dermis, suggesting that at least some 
langerin-positive DCs in the dermis can 
develop independently of LCs and differ 
from migratory LCs en route to the LNs. 
Additional data from Ginhoux showed 
that, in contrast to LCs, dermal lan-
gerin-positive DCs derive from blood 
precursors that are recruited to the skin 
in the steady state. He also showed that 
dermal langerin-positive DCs capture 
and present skin-derived antigens in 
the draining LNs. These results indicate 
that care must be taken in identify-
ing LCs beyond the epidermis and that 
truly unique markers to LCs remain to 
be identified. These results also reveal 
for the first time the capacity of blood-
derived DCs to constitutively patrol the 
skin, uncovering a previously unappre-
ciated element of skin immunosurveil-
lance that is likely to impact the design 
of vaccine strategies.
Regulation of Langerhans cell migration 
to the lymph nodes
Several studies established CCR7 as 
a key element in the migration of LCs 
to the LNs in inflamed state (Förster et 
al., 1999). CCR7 is not expressed on 
immature LCs present in quiescent skin 
but can be triggered by inflammatory 
cytokines (Cyster, 2000). These observa-
tions led to the concept that inflamma-
tory cytokines upregulate CCR7 expres-
sion on LCs, allowing them to migrate 
toward CCR7 ligands expressed by the 
lymphatic endothelium and LN stromal 
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cells. However, LCs can also leave the 
skin and migrate to the LNs in the steady 
state, and the mechanisms that regu-
late LC steady-state migration remain 
unclear. Reinhold Förster (Hannover, 
Germany) discussed the importance of 
CCR7 in regulating LC migration to the 
draining LNs in the steady state (Ohl et 
al., 2004), but how CCR7 is induced on 
quiescent LCs remains a puzzle.
Sonja Zahner (Björn Clausen’s labo-
ratory, Amsterdam, The Netherlands) 
may have a key to this question. 
Zahner’s hypothesis suggests that the 
E-cadherin—β-catenin complex plays 
a key role in CCR7 expression. β-
Catenin is the central, nonredundant 
component of the canonical Wnt sig-
naling pathway and mediates regula-
tion of gene expression. β-Catenin 
is also a member of the E-cadherin–
catenin complex and contributes to 
cell adhesion. In particular, LCs and 
keratinocytes form adherens junctions 
containing E-cadherin, and downregu-
lation of E-cadherin coincides with LC 
maturation and emigration from the 
epidermis. Zahner’s hypothesis is that 
E-cadherin–β-catenin signals may play 
a critical role in the control of LC func-
tion in immune regulation. This is based 
on work from Ira Mellman’s lab (New 
Haven, CT) demonstrating that dis-
rupting E-cadherin binding or overex-
pressing β-catenin in vitro induces DC 
maturation and DC expression of CCR7 
without secretion of proinflammatory 
cytokines (Jiang et al., 2007). To unravel 
the capacity of the Wnt and E-cadherin 
pathways to govern LC/DC function 
in vivo, Dr. Zahner recently generated 
mice with LC/DC-specific expression of 
constitutively active β-catenin and with 
LC/DC-specific β-catenin or E-cadherin 
deficiency. Surprisingly, the LC net-
work in these mice was still intact and 
indistinguishable from that of wild-type 
animals. Nevertheless, all three LC/DC-
specific mutants demonstrated dysregu-
lated contact hypersensitivity (CHS) 
responses to topical haptens, and, in 
particular, the β-catenin-stabilization 
mutant failed to mount any measurable 
ear-swelling response.
Gwendalyn Randolph (New York, 
NY) reported that two contact sensitiz-
ers, fluorescein isothiocyanate (FITC) 
and tetramethylrhodamine isothiocya-
nate (TRITC), that are often assumed 
to trace DC migration from skin iden-
tically in fact behave distinctly and 
may not label precisely the same 
populations of DCs. The use of TRITC 
as a tracer of migration has become 
popular as the use of green fluorescent 
protein (GFP)–positive mice, includ-
ing langerin-GFP mice, has increased. 
These data raise the possibility that the 
large body of literature on the regula-
tion of DC migration after FITC paint-
ing may not apply fully to TRITC-based 
assays. Dr. Randolph also presented 
data illustrating that some DCs that 
carry fluorescent tracers to the LNs are, 
surprisingly, found in the adipose tis-
sue outside of the draining LNs. These 
DCs may be skin DCs that miss the tar-
get of the LNs and instead prematurely 
migrate out of the lymphatics into adi-
pose tissue. Alternatively, the adipose 
tissue may serve as a source of migra-
tory DCs, because there is no formal 
proof that the contact sensitizer-bear-
ing DCs all derive from skin after its 
application epicutaneously.
Langerhans cells and innate immunity
The roles of LCs in immune respons-
es—and how these roles differ, if at 
all, from those of other populations of 
DCs—is a matter of intense research 
in skin immunology. Matthias Gunzer 
(Braunschweig, Germany) presented an 
interesting model with which to assess 
microbial capture by LCs in clinically 
relevant conditions. He showed that 
DCs are very efficient at capturing fungi 
in a 3D in vitro model, in contrast with 
how they performed in a 2D culture 
model, indicating that LCs likely have 
a role in capturing parasites in the skin 
and that the design of any in vitro exper-
iments conducted to assess LC function 
should take into account the normal 3D 
structural properties of the skin. Jürgen 
Harder (Kiel, Germany) examined the 
potential role of antimicrobial cutane-
ous proteins in skin immunity. By cul-
turing psoriatic-scale extracts with bac-
terial components to search for antimi-
crobial properties, he identified the first 
antimicrobial peptide: β−defensin 2, a 
peptide expressed in the upper layer of 
inflamed epidermis with activity against 
pseudomonas, Candida albicans, and 
Staphylococcus aureus (Harder et al., 
1997). Using the same strategy, Harder 
discussed the recent identification of 
several other antimicrobial peptides 
(Glaser et al., 2005).
Role of Langerhans cells in contact 
allergies
Bettina Jux from Charlotte Esser's 
laboratory (Düsseldorf, Germany) dis-
cussed the role of LCs in allergies to 
low-molecular-weight chemicals. Jux 
and colleagues discovered that LCs 
express the arylhydrocarbon recep-
tor, a transcription factor that controls 
the enzymes needed for the biotrans-
formation of harmless low-molecular-
weight chemicals, and that LCs isolated 
from mice that lack the arylhydrocar-
bon receptor poorly upregulate CD40 
and CD80 after in vitro maturation. 
Based on these data, Jux discussed the 
possibility that arylhydrocarbon-recep-
tor mutations might interfere with the 
potential of LCs to tolerize against low-
molecular-weight chemicals.
Role of Langerhans cells in viral 
immunity
Teunis Geijtenbeek (Amsterdam, The 
Netherlands) discussed the importance 
of C-type lectin receptors (CLRs) as part 
of the pattern recognition receptor fam-
ily and discussed their role in cutane-
ous immunity. Focusing on two CLRs—
DC-SIGN and langerin—Geijtenbeek 
explained that both can be involved in 
the recognition of similar pathogens, 
including HIV. However, the differen-
tial expression of DC-SIGN and lan-
gerin by DC compartments in the skin 
select for preferential recognition in 
vivo. Langerin expression is restricted 
to epidermal LCs, whereas DC-SIGN is 
expressed on dermal DCs and dermal 
macrophages. In addition, CLRs can 
have opposite functions in viral immu-
nity. While DC-SIGN binds to HIV-1 
to facilitate its transmission to CD4 
T cells, langerin captures and targets 
HIV to the Birbeck granules, where it 
gets degraded, preventing T-cell infec-
tion. Lot de Witte, from Geijtenbeek’s 
group, demonstrated that a similar fate 
awaits measles viruses that are cap-
tured by langerin. Marein de Jong, also 
from the Geijtenbeek group, illustrated 
that HSV facilitates HIV transmission 




LCs. Downregulation of langerin on LCs 
favors HIV capture by the viral receptors 
CD4 and CCR5 (also expressed on LCs) 
and prevents HIV routing to the Birbeck 
granules and its degradation, thereby 
facilitating its transmission to T cells.
Targeting Langerhans cells in vivo to 
manipulate the immune response
Targeting Langerhans cells with mono-
clonal antibodies. A strong effort is 
being made to target specific DC subsets 
to tune the immune response. Vincent 
Flacher from Nikolaus Romani’s labo-
ratory (Innsbruck, Austria) discussed in 
vivo targeting approaches using intra-
dermal injection of antigens coupled 
to two different lectin-binding mono-
clonal antibodies, including antibody 
to DEC-205 and langerin (also called 
L31). Flacher found that these antibod-
ies can reach the epidermis less than an 
hour before being internalized by LCs. 
Targeted LCs migrate to the dermis to 
form dermal cords and upon injection 
of proinflammatory signals are induced 
to migrate to the skin draining LNs. L31 
targets LCs very efficiently but does 
not target CD8+ langerinlow DCs in the 
LNs. These studies are very relevant to 
the design of targeting-approach strat-
egies for modulating specific immune 
responses in vivo.
Deleting Langerhans cells: what 
we have learned from the DTR-lan-
gerin transgenic mice? The DTR-lan-
gerin transgenic mouse model has 
been used in a large number of stud-
ies, thanks to the generosity of Bernard 
Malissen (Marseille, France) and Björn 
Clausen (Amsterdam, The Netherlands) 
(Kissenpfennig et al., 2005; Bennett et 
al., 2005).
Several groups reported that condi-
tional ablation of LCs after DT adminis-
tration does not affect adaptive immune 
responses. For example, Fabienne 
Anjuère (Nice, France) examined the 
contribution of vagina LCs to CD8-spe-
cific immune responses induced after 
intravaginal administration of a chol-
era toxin–based vaccine. She noted 
that the response was identical in the 
presence or absence of LCs. Likewise, 
Angelika Stöcklinger (Salzburg, Austria) 
showed that gene-gun-induced immune 
responses remained unchanged in the 
presence or absence of LCs.
In contrast with the studies above, 
several groups were able to identify 
a role for LCs in cutaneous immu-
nity. Simone Zimmerli (Geneva, 
Switzerland) discussed the role of thy-
mic stromal lymphopoietin (TSLP) and 
LCs in CHS. TSLP is known to prime 
DCs (Soumelis and Liu, 2004), includ-
ing LCs (Ebner et al., 2007), to induce 
pro-allergic cytokines by T cells. Dr. 
Zimmerli demonstrated that TSLP 
mRNA increases after epicutaneous 
FITC sensitization and CHS response 
to FITC was reduced in TSLP recep-
tor–deficient mice. Interestingly, CHS 
to FITC was also strongly decreased 
after conditional ablation of LCs. 
Patrizia Stoitzner (Innsbruck, Austria) 
examined the role of LCs in antitumor 
immunity induced by an ovalbumin-
containing cream applied onto a barri-
er of disrupted skin using a B16 tumor 
melanoma mouse model. She showed 
here that the antitumor response was 
strongly reduced in the absence of 
LCs and that the need for LCs was 
most stringent when a low dose of 
antigen was present in the vaccine. 
This argument was further discussed 
by Björn Clausen (Amsterdam, The 
Netherlands), who pointed out that 
LC contribution to CHS is directly 
correlated with the amount of hapten 
painted onto the skin. Using langerin-
DTR mice, Clausen demonstrated that 
CHS reactions in the absence of LCs 
were more strongly reduced when a 
low dose of oxazolone was applied to 
the skin, most likely due to limited dis-
semination of the antigen into the der-
mis (Bennett et al., 2007).
Carlos Ardavin (Madrid, Spain) sum-
marized recent published data showing 
that after leishmania infection of the 
skin, freshly recruited circulating mono-
cytes that differentiate into DCs in the 
dermis are responsible for the induc-
tion of T-cell-specific immune response 
(Leon et al., 2007). It is therefore likely 
that depletion of LCs and dermal DCs 
in this model will not alter antileishma-
nia immunity.
All together, these studies suggest 
that LCs are required to induce CHS or 
antigen-specific CD8 response when 
antigens are delivered exclusively to 
the epidermis. In contrast, DCs other 
than LCs are able to induce adaptive 
immune response, when antigens dif-
fuse out of the epidermis. For exam-
ple, gene-gun immunization strategies 
deliver antigens to the epidermis and 
the dermis, and it is likely that LCs, 
dermal DCs, and potentially freshly 
recruited monocyte-derived DCs are 
equally able to capture and pres-
ent cutaneous antigens in this model. 
Antigens present in mucosal cholera 
toxin–based vaccine are also likely to 
diffuse beneath the epithelium, allow-
ing both LCs and submucosal DCs to 
capture and present antigen-derived 
epitopes. The capacity of DCs other 
than LCs to present antigens will help 
explain why, in some models, ablation 
of LCs does not significantly alter the 
fate of the immune response.
Role of Langerhans cells in tolerance
Dan Kaplan (Minneapolis, MN) dis-
cussed the role of LCs in immune tol-
erance. The basis for this hypothesis 
was shown in an LC-deficient mouse 
model, in which an attenuated form of 
the DT is expressed under the human 
langerin promoter, leading to the spe-
cific killing of mouse LCs in the epi-
dermis (Kaplan et al., 2005). Unlike 
the langerin-DTR mice, only epidermal 
LCs are deleted and not langerin-posi-
tive DCs in the dermis and secondary 
lymphoid tissue. These mice have an 
increased CHS response to topical hap-
tens compared with wild-type mice, 
leading to the hypothesis that LCs play 
a critical role in the modulation of cuta-
neous immune response. Consistent 
with this hypothesis and extending it 
to a different assay system, more recent 
data were presented that indicate that 
male → female grafts on the FVB back-
ground, which are normally accepted, 
are rejected if the donor skin lacks epi-
dermal LCs.
In the last session of the meeting, 
Thomas Schwarz (Kiel, Germany) 
addressed the role played by LCs in 
UV-induced immune suppression and 
induction of T-regulatory cells. He dis-
cussed previous data showing that UV 
radiation mediates the induction of 
T-regulatory cells through LCs har-
boring UV-induced DNA damage 
(Schwarz et al., 2005). However, more 
recent preliminary data using langer-
in-DTR mice suggest that UV-induced 
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T-regulatory cells may still develop in 
the absence of LCs.
New tools in Langerhans cell research
Another session was dedicated to the 
development of new tools to facili-
tate LC research. The DTR-langerin 
mouse model was much discussed. 
Jean Davoust discussed the impor-
tance of live imaging in LC biology 
and presented beautiful two-photon 
images illustrating that LCs can detach 
antigen cargo from keratinocytes in 
the steady state. Two presentations 
emphasized the importance of skin-
equivalent models for the pharma-
ceutical industry. Francoise Rousset 
(L’Oréal Advanced Research, Aulnay-
sous-Bois, France) discussed the rele-
vance of reconstructed human skin for 
the cosmetics industry. Striking images 
of an epidermal equivalent contain-
ing keratinocytes, melanocytes, and 
CD34-derived LC-like cells were pre-
sented. LC-like cells that differentiate 
in this model contained Birbeck gran-
ules; they secreted inflammatory cyto-
kines and were able to induce T-cell 
immune response. Rousset also argued 
that CD34-derived LCs represent a 
major limitation to the extended use 
of skin equivalents in drug screening 
and pointed out that LC-like cell lines 
are currently being examined as a 
potential replacement source. Nicolas 
Bechetoille (BASF, Lyon, France) 
described the first human reconstruct-
ed skin model system with an epider-
mal and dermal equivalent compo-
nent containing LC-like and dermal 
DC-like cells. In this model, LC- and 
dermal DC-like cells segregated in the 
expected compartments. Both sources 
of DCs were able to upregulate CCR7 
in response to inflammatory signals 
and secrete inflammatory cytokines 
(Bechetoille et al., 2007).
Personal views on Langerhans cells
In this session investigators were asked 
to summarize the impact of recent 
research—their own or others’—on 
what we know about LCs and to out-
line areas of LC research that need to 
be explored further.
Georg Stingl (Vienna, Austria) noted 
how much more needs to be learned 
about the role of LCs in the control of 
keratinocyte proliferation and in dis-
eases such as psoriasis. Stingl empha-
sized the multiple roles of langerin, 
including its role in the presentation 
of glycolipid antigens, its capacity to 
give access to the nonclassic CD1-
dependent antigen pathway, and its 
role in viral recognition and antiviral 
immunity. Dr. Stingl also discussed his 
recent data on a somewhat unexpected 
innate defense function of DCs show-
ing that tumoricidal dendritic cells 
were induced by imiquimod treatment 
of patients with basal cell carcinoma 
(Stary et al., 2007).
Karolina Palucka (Dallas, TX) dis-
cussed the role of human LCs and 
dermal DCs in T-cell responses. 
Human LCs and dermal DCs were 
either generated from CD34+ progeni-
tors or directly isolated from human 
skin, and DCs from both sources led 
to similar functional responses. Data 
strongly supporting the capacity of 
human LCs to cross-present soluble 
antigens to CD8 T cells and to induce 
very potent CD8 cytotoxic antitumor-
al response were presented. LCs were 
also shown to be very potent at induc-
ing allogeneic T-helper 2 responses. 
In contrast, dermal DCs were shown 
to be unable to cross-present antigens 
and less efficient at priming CD4 and 
CD8 T cells while inducing potent T-
helper follicular T cells. Dr. Palucka 
emphasized the similarity between 
these results and results obtained by 
Malissen’s group (Kissenpfennig et 
al., 2005) that demonstrate that in 
mouse-skin draining LNs, migratory 
LCs are located mostly in the T-cell 
areas, whereas dermal DCs localize 
near the B-cell follicle where T-helper 
follicular T cells are present.
Miriam Merad (New York, NY) 
reviewed past and recent studies on LC 
ontogeny, as indicated above (Merad 
et al., 2002; Ginhoux et al., 2006). She 
also discussed similarities between the 
properties and mechanisms that regu-
late human and mouse LC homeosta-
sis. Data indicating that human LCs 
proliferate in situ in quiescent skin 
were presented. Also presented were 
results of prospective clinical trials 
examining the turnover of LCs and der-
mal DCs in patients who receive either 
a reduced-intensity or full-intensity 
conditioning regimen prior to grafting 
of allogeneic hematopoietic cells.
Do Langerhans cells deserve a meeting 
on their own?
Nikolaus Romani (Innsbruck, Austria) 
summarized the main findings of the 
meeting and emphasized the impor-
tance of new tools in fostering LC 
research. LCs are attractive to a variety 
of physicians, scientists, and pharma-
ceutical organizations. Poised at the 
interface with the environment, LCs 
play a role in a variety of human diseas-
es and are being studied by scientists 
with diverse interests.
In medicine, LCs are studied by 
dermatologist for their role in numer-
ous skin diseases including psoriasis, 
atopic dermatitis, and skin allergies. 
They are also studied by specialists in 
infectious disease, because the skin 
is a frequent site of infection, and by 
oncologists because of their role in a 
number of prevalent cancers such as 
squamous- and basal-cell carcinoma 
and melanoma. They are of great inter-
est to immunologists because LCs are 
the most accessible nonlymphoid DC 
population in mice and humans, and to 
photobiologists because LCs are a criti-
cal target of UV-induced injuries. LCs 
are also actively studied by the cosmet-
ics industry for their potential role in 
cream-induced adverse responses and 
by the vaccine industry for their key 
role in vaccine-induced immunity. So, 
yes, LCs do deserve a meeting on their 
own, because it is through these diverse 
interactions that important discoveries 
are made.
The 11th International Workshop on 
Langerhans Cells will be held in Funchal, 
Madeira, Portugal, 3–6 September 2009 
(http://www.lc2009.at).
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